Publications by authors named "Franklin Johnson"

Claim this Profile
C
Correction: Pharmacokinetic evaluation of single-dose migalastat in non-Fabry disease subjects with ESRD receiving dialysis treatment, and use of modeling to select dose regimens in Fabry disease subjects with ESRD receiving dialysis treatment.
Franklin K Johnson, Shirley Wu, Ginny Schmith, Hadis Williams, Jasmine Rutecki

PLoS One· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).
Barry J Byrne, Benedikt Schoser, Priya S Kishnani, Drago Bratkovic, Paula R Clemens, Franklin Johnson

J Neurol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease.
Barry J Byrne, Giancarlo Parenti, Benedikt Schoser, Ans T van der Ploeg, Hung Do, Franklin K Johnson

Front Neurol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic evaluation of single-dose migalastat in non-Fabry disease subjects with ESRD receiving dialysis treatment, and use of modeling to select dose regimens in Fabry disease subjects with ESRD receiving dialysis treatment.
Franklin K Johnson, Shirley Wu, Ginny Schmith, Hadis Williams, Jasmine Rutecki

PLoS One· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Understanding the evolution of competing institutional logics in the marketization of care: A stage model analysis of Australia's National Disability Insurance Scheme.
Fanny Salignac, Ralf Barkemeyer, Elizabeth Franklin-Johnson, Tulin Dzhengiz

Health Policy· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cipaglucosidase alfa plus miglustat: linking mechanism of action to clinical outcomes in late-onset Pompe disease.
Barry J Byrne, Giancarlo Parenti, Benedikt Schoser, Ans T van der Ploeg, Hung Do, Franklin K Johnson

Front Neurol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).
Barry J Byrne, Benedikt Schoser, Priya S Kishnani, Drago Bratkovic, Paula R Clemens, Franklin Johnson

J Neurol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics of Oral Migalastat in Adolescents and Adults With and Without Renal Impairment.
Cathrine Leonowens, Virginia Schmith, Jie Zhou, Yi Shuan Wu, Vijay Ivaturi, Franklin K Johnson

Clin Pharmacol Drug Dev· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Migalastat Tissue Distribution: Extrapolation From Mice to Humans Using Pharmacokinetic Modeling and Comparison With Agalsidase Beta Tissue Distribution in Mice.
Yi Shuan Wu, Richie Khanna, Virginia Schmith, Yi Lun, Jin-Song Shen, Franklin K Johnson

Clin Pharmacol Drug Dev· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biochemometric Analysis of Fatty Acid Amide Hydrolase Inhibition by Echinacea Root Extracts.
Rui Liu, Kelly Burkett, Michel Rapinski, John T Arnason, Franklin Johnson

Planta Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spontaneous tension pneumothorax and acute pulmonary emboli in a patient with COVID-19 infection.
Ruhaid Khurram, Franklin T F Johnson, Revati Naran, Samanjit Hare

BMJ Case Rep· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders.
Andrew E Mulberg, Christina Bucci-Rechtweg, Joseph Giuliano, David Jacoby, Franklin K Johnson

Orphanet J Rare Dis· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative bioavailability and the effect of meal type and timing on the pharmacokinetics of migalastat in healthy volunteers.
Franklin K Johnson, Paul N Mudd, Salim G Janmohamed

Clin Pharmacol Drug Dev· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α.
Priya Kishnani, Mark Tarnopolsky, Mark Roberts, Kumarswamy Sivakumar, Majed Dasouki, Franklin K Johnson

Mol Ther· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
Derralynn A Hughes, Kathleen Nicholls, Suma P Shankar, Gere Sunder-Plassmann, David Koeller, Franklin Johnson

J Med Genet· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.
Dominique P Germain, Derralynn A Hughes, Kathleen Nicholls, Daniel G Bichet, Roberto Giugliani, Franklin Johnson

N Engl J Med· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.
David G Warnock, Daniel G Bichet, Myrl Holida, Ozlem Goker-Alpan, Kathy Nicholls, Franklin K Johnson

PLoS One· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptome changes in apple peel tissues during CO2 injury symptom development under controlled atmosphere storage regimens.
Franklin T Johnson, Yanmin Zhu

Hortic Res· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function.
Franklin K Johnson, Paul N Mudd, Tara DiMino, Jennie Vosk, Sheela Sitaraman

Clin Pharmacol Drug Dev· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the safety, pharmacodynamic, and pharmacokinetic effects following oral coadministration of immediate-release morphine with ethanol in healthy male participants.
Beatrice Setnik, Marta Sokolowska, Franklin Johnson, John Oldenhof, Myroslava Romach

Hum Psychopharmacol· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of Migalastat HCl and Effects on Agalsidase Activity in Healthy Volunteers.
Franklin K Johnson, Paul N Mudd, Alexander Bragat, Mathews Adera, Pol Boudes

Clin Pharmacol Drug Dev· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of alcohol on the pharmacokinetics of morphine sulfate and naltrexone hydrochloride extended release capsules.
Franklin K Johnson, Sabrina Ciric, Sophie Boudriau, James Kisicki, Joseph Stauffer

J Clin Pharmacol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Morphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability.
Franklin Johnson, Beatrice Setnik

Pain Physician· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users.
Lynn R Webster, Franklin K Johnson, Joseph Stauffer, Beatrice Setnik, Sabrina Ciric

Drugs R D· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy of morphine sulfate and naltrexone hydrochloride extended release capsules, a novel formulation containing morphine and sequestered naltrexone, in patients with chronic, moderate to severe pain.
Lynn R Webster, Randall Brewer, Chao Wang, Doreen Sekora, Franklin K Johnson

J Pain Symptom Manage· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis